5篇
您的检索式：作者名="Stanley Perlman"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein显示文摘最新新兴的中东呼吸症候群 coronavirus (MERS-CoV ) 能在人引起严重、致命的急性呼吸疾病。尽管有全球努力,潜力为一联系在未来流行不能被排除。有效相对的措施的发展是迫切的。MERS-CoV-specific 抗病毒的药或疫苗是还没可得到的。使用 MERS-CoV (MERS-RBD ) 的尖铁受体绑定领域使老鼠免疫,我们识别了二抵销 monoclonal 抗体(mAbs ) 4C2 和 2E6。两 mAbs potently 与高功效在 vitro 绑在 MERS-RBD 和块病毒入口。我们进一步由使在 Fab 碎片和 RBD 之间的建筑群结晶调查了他们中立化的机制,并且解决了 4C2 Fab/MERS-RBD 建筑群的结构。结构证明 4C2 认出部分重叠的 epitope 在 MERS-RBD 的受体绑定脚印,从而由位的阻碍者和接口残余竞争防碍病毒 / 受体相互作用。2E6 也堵住受体绑定,并且为绑定与 4C2 竞争到 MERS-RBD。基于结构,我们进一步由保存仅仅 paratope 残余并且从人的免疫球蛋白与对应物代替留下的氨基酸使 4C2 人性化。人性化的 4C2 (4C2h ) 抗体支撑了类似的抵销的活动和生物化学的特征到父母老鼠抗体。最后,我们证明 4C2h 能显著地在感染 MERS-CoV 的 Ad5-hCD26-transduced 鼠标的肺消除病毒 titers,因此在临床的设置为预防和治疗代表一个有希望的代理人。 | Yan Li YuhuaWan Peipei Liu Jincun Zhao Guangwen Lu Jianxun Qi Qihui Wang Xuancheng LU Ying Wu Weniun Liu Buchang Zhang Kwok-Yung Yuen Stanley Perlman George F Gao Jinghua Yan | 2015 | Cell Research2015，25，11： | 14 |
| 2 | Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus显示文摘 | Naru Zhang Rudragouda Channappanavar Cuiqing Ma Lili Wang Jian Tang Tania Garron Xinrong Tao Sumaiya Tasneem Lu Lu Chien-Te K Tseng Yusen Zhou Stanley Perlman Shibo Jiang Lanying Du | 2016 | Cellular & Molecular Immunology2016，13，2： | 12 |
| 3 | Pathogenic Role for Virus-Specific CD4 T Cells in Mice with Coronavirus-Induced Acute Encephalitis显示文摘 | Daniela Anghelina Lecia Pewe Stanley Perlman | 2006 | The American Journal of Pathology2006，，1： | 1 |
| 4 | Lipid nanoparticle-mRNA:another step in the fight against COVID-19显示文摘One of the most important therapies useful in preventing progression of COVID-19 in high-risk patients are monoclonal antibodies targeting the surface glycoprotein.In a recent work in Cell Research,Deng et al.use lipid nanoparticles encapsulating mRNA encoding SARS-CoV-2-specific antibody chains to protect animals from lethal infection.The COVID-19 global pandemic poses immense challenges to global health.Rapid spread of the disease has prompted intense research to identify therapeutics and vaccines.Currently,vaccines are the most effective approach to preventing COVID-19 but the emergence of variants of concern(VOC)has compromised vaccine efficacy.Also,vaccines cannot be used as treatment so are not useful in critically ill patients.Considering these limitations,there is an urgent need for the development of therapeutic approaches.In August 2020,Food and Drug Administration(FDA)issued an Emergency Use Authorization(EUA)for convalescent plasma for the treatment of hospitalized patients with COVID-19,but later clinical trials showed that this intervention was generally not effective.1 Subsequently,several potent monoclonal antibodies(mAbs)with anti-viral activity in vitro and in preclinical studies were identified and shown to be effective in clinical trials.These antibodies are most effective when delivered prophylactically,or more feasibly,to patients in the early stages of the disease.2 There are two major challenges to the use of mAb-based therapy:the cost of large-scale production of these antibodies is high and mAbs are generally delivered intravenously,which is problematic in low resource and overburdened clinical settings. | Abhishek Kumar Verma Stanley Perlman | 2022 | Cell Research2022，32，5： | 0 |
| 5 | Proviral role of caspase-6 in coronavirus infections显示文摘Pathogenic human coronaviruses induce apoptosis in infected cells.Caspase-6 activated under apoptotic conditions proteolytically cleaves the nucleocapsid protein into IFN-I antagonists that enhance virus replication,suggesting that caspase-6 has a proviral role in the coronavirus life cycle. | Lok-Yin Roy Wong Stanley Perlman | 2023 | Cell Research2023，33，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员